SG11201603462SA - Compositions and methods useful in treatment of lower urinary tract symptoms, benign prostatic hyperplasia, erectile dysfunction - Google Patents
Compositions and methods useful in treatment of lower urinary tract symptoms, benign prostatic hyperplasia, erectile dysfunctionInfo
- Publication number
- SG11201603462SA SG11201603462SA SG11201603462SA SG11201603462SA SG11201603462SA SG 11201603462S A SG11201603462S A SG 11201603462SA SG 11201603462S A SG11201603462S A SG 11201603462SA SG 11201603462S A SG11201603462S A SG 11201603462SA SG 11201603462S A SG11201603462S A SG 11201603462SA
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- treatment
- urinary tract
- erectile dysfunction
- benign prostatic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Emergency Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361902376P | 2013-11-11 | 2013-11-11 | |
PCT/US2014/064961 WO2015070203A1 (fr) | 2013-11-11 | 2014-11-11 | Compositions et méthodes utiles dans le traitement des symptômes des voies urinaires inférieures, de l'hyperplasie prostatique bénigne, et de la dysfonction érectile |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201603462SA true SG11201603462SA (en) | 2016-05-30 |
Family
ID=53042226
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201910781SA SG10201910781SA (en) | 2013-11-11 | 2014-11-11 | Compositions and methods useful in treatment of lower urinary tract symptoms, benign prostatic hyperplasia, erectile dysfunction |
SG11201603462SA SG11201603462SA (en) | 2013-11-11 | 2014-11-11 | Compositions and methods useful in treatment of lower urinary tract symptoms, benign prostatic hyperplasia, erectile dysfunction |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201910781SA SG10201910781SA (en) | 2013-11-11 | 2014-11-11 | Compositions and methods useful in treatment of lower urinary tract symptoms, benign prostatic hyperplasia, erectile dysfunction |
Country Status (21)
Country | Link |
---|---|
US (5) | US20160324911A1 (fr) |
EP (2) | EP3782634B1 (fr) |
JP (2) | JP6966196B2 (fr) |
KR (2) | KR20230004886A (fr) |
CN (2) | CN105848663A (fr) |
AU (1) | AU2014346415B2 (fr) |
BR (1) | BR112016010509B1 (fr) |
CA (1) | CA2928631A1 (fr) |
CL (1) | CL2016001109A1 (fr) |
CR (1) | CR20160254A (fr) |
ES (1) | ES2860773T3 (fr) |
IL (1) | IL245552B (fr) |
MX (1) | MX2016005810A (fr) |
MY (1) | MY184225A (fr) |
NZ (1) | NZ719268A (fr) |
PH (1) | PH12016500780A1 (fr) |
PL (1) | PL3068414T3 (fr) |
RU (1) | RU2696584C1 (fr) |
SG (2) | SG10201910781SA (fr) |
WO (1) | WO2015070203A1 (fr) |
ZA (1) | ZA201602941B (fr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2014346415B2 (en) * | 2013-11-11 | 2020-04-23 | Naturex-Dbs Llc | Compositions and methods useful in treatment of lower urinary tract symptoms, benign prostatic hyperplasia, erectile dysfunction |
WO2018134962A1 (fr) * | 2017-01-20 | 2018-07-26 | マルカイコーポレーション株式会社 | Agent d'amélioration pour la pollakiurie |
CN107647387A (zh) * | 2017-08-15 | 2018-02-02 | 孟广千 | 用于补膀胱的保健食品 |
IT201800007473A1 (it) | 2018-07-24 | 2020-01-24 | Sistema di aggancio ad evidenza di manomissione, procedimento per la realizzazione di detto sistema di aggancio, contenitore comprendente detto sistema di aggancio ed uso di quest'ultimo | |
JP7219907B2 (ja) * | 2018-07-25 | 2023-02-09 | 株式会社 沖縄リサーチセンター | 下部尿路症状改善用組成物 |
JP6738388B2 (ja) * | 2018-09-27 | 2020-08-12 | マルカイコーポレーション株式会社 | 頻尿の改善剤 |
CA3160517A1 (fr) * | 2019-11-08 | 2021-05-14 | Cj Cheiljedang Corporation | Composition a utiliser pour reduire les defauts de gout et d'arome comprenant un acide chlorogenique, un acide cafeique et un acide quinique |
CN116056761A (zh) * | 2020-08-31 | 2023-05-02 | 建国大学全球本土化产学合作基金会 | 包含翅果连翘提取物作为活性成分的用于治疗雄激素受体相关疾病的药物组合物 |
WO2022189010A1 (fr) * | 2021-03-07 | 2022-09-15 | Givaudan Sa | Méthodes et compositions pour le traitement et la prévention d'infections des voies urinaires |
KR102388984B1 (ko) * | 2021-11-16 | 2022-04-20 | 재단법인 전남바이오산업진흥원 | 모새나무 열매 추출물을 유효성분으로 포함하는 전립선 비대증 예방 또는 치료용 약학조성물 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
US5698155A (en) | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US5525341A (en) * | 1992-10-09 | 1996-06-11 | Jlb, Inc. | Partially purified cranberry anti-adhesion activity |
IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
US6231866B1 (en) * | 1998-04-30 | 2001-05-15 | Douglas G. Mann | Infused vegetable, fruit, herb, and/or seed fiber product and dietary supplements containing same |
US20010025059A1 (en) | 2000-01-10 | 2001-09-27 | Kastke Floyd A. | Composition and method for treating non-bacterial prostatitis |
US6391345B1 (en) | 2000-05-12 | 2002-05-21 | Tim Heeg | Cranberry seed oil, cranberry seed flour and a method for making |
JP2001342142A (ja) * | 2000-06-01 | 2001-12-11 | Nissui Pharm Co Ltd | 泌尿器系疾患予防治療用組成物 |
US7270837B2 (en) * | 2003-11-10 | 2007-09-18 | Rutgers, The State University Of New Jersey | Anti-inflammatory cranberry flavonol extract preparations |
CA2555121A1 (fr) * | 2004-02-04 | 2005-08-25 | Foamix Ltd. | Mousse cosmetique et pharmaceutique comprenant des matieres solides |
JP2008500027A (ja) * | 2004-05-03 | 2008-01-10 | ノーザン ライツ フード プロセシング,エルエルシー | ベリーオイルおよび製品 |
US8153166B2 (en) * | 2006-06-08 | 2012-04-10 | Chih-Hsiung Lin | Composition for prophylaxis or treatment of urinary system infection and method thereof |
EP2170352A1 (fr) * | 2007-06-27 | 2010-04-07 | Coloplast A/S | Traitement d'infections des voies urinaires avec un mélange à base de saponine et d'un antibiotique |
CN101095764B (zh) * | 2007-07-13 | 2010-05-19 | 天津天狮生物发展有限公司 | 具有辅助治疗女性泌尿道感染的保健食品 |
US8173178B1 (en) | 2007-08-03 | 2012-05-08 | Decas Botanical Synergies, Llc | Compositions and methods for controlling metabolic syndrome using whole fruit-derived cranberry ingredient profile enriched in stress adapted bioactives (SABs) |
US20090175843A1 (en) * | 2008-01-08 | 2009-07-09 | Medical Nutrition Usa, Inc. | Composition for prevention or treatment of urinary tract infection |
US20090180999A1 (en) * | 2008-01-11 | 2009-07-16 | U.S. Nutraceuticals, Llc D/B/A Valensa International | Method of preventing, controlling and ameliorating urinary tract infections using cranberry derivative and d-mannose composition |
US20110064706A1 (en) | 2008-01-11 | 2011-03-17 | U.S. Nutraceuticals, Llc D/B/A Valensa International | Method of preventing, controlling and ameliorating urinary tract infections and supporting digestive health by using a synergistic cranberry derivative, a d-mannose composition and a proprietary probiotic blend |
EP2156835A1 (fr) * | 2008-08-19 | 2010-02-24 | Sanofi-Aventis | Nouvelle utilisation thérapeutique de la drotaverine |
CA2787055A1 (fr) | 2010-01-15 | 2011-07-21 | Ocean Spray Cranberries, Inc. | Procede d'extraction d'un compose de feuilles de canneberge et produits apparentes |
CN101999648B (zh) * | 2010-10-11 | 2012-10-31 | 宝鸡市虹源生物科技有限公司 | 蔓越橘果实中花色苷及原花青素类成分的提取方法 |
JP2012171899A (ja) * | 2011-02-21 | 2012-09-10 | Unitika Ltd | 尿路感染症予防改善剤 |
FR2972328A1 (fr) * | 2011-03-07 | 2012-09-14 | Walmark A S | Complement alimentaire augmentant la protection de l'epithelium des voies urinaires basses contre les infections a repetition |
US20130122146A1 (en) * | 2011-11-16 | 2013-05-16 | Decas Botanical Synergies, Llc | Process for Spray Drying Botanical Food |
AU2014346415B2 (en) * | 2013-11-11 | 2020-04-23 | Naturex-Dbs Llc | Compositions and methods useful in treatment of lower urinary tract symptoms, benign prostatic hyperplasia, erectile dysfunction |
-
2014
- 2014-11-11 AU AU2014346415A patent/AU2014346415B2/en active Active
- 2014-11-11 ES ES14860917T patent/ES2860773T3/es active Active
- 2014-11-11 NZ NZ719268A patent/NZ719268A/en unknown
- 2014-11-11 PL PL14860917T patent/PL3068414T3/pl unknown
- 2014-11-11 SG SG10201910781SA patent/SG10201910781SA/en unknown
- 2014-11-11 JP JP2016553265A patent/JP6966196B2/ja active Active
- 2014-11-11 EP EP20199906.7A patent/EP3782634B1/fr active Active
- 2014-11-11 MY MYPI2016701485A patent/MY184225A/en unknown
- 2014-11-11 EP EP14860917.5A patent/EP3068414B1/fr active Active
- 2014-11-11 CR CR20160254A patent/CR20160254A/es unknown
- 2014-11-11 MX MX2016005810A patent/MX2016005810A/es active IP Right Grant
- 2014-11-11 BR BR112016010509-5A patent/BR112016010509B1/pt active IP Right Grant
- 2014-11-11 KR KR1020227042946A patent/KR20230004886A/ko not_active Application Discontinuation
- 2014-11-11 CN CN201480070244.5A patent/CN105848663A/zh active Pending
- 2014-11-11 WO PCT/US2014/064961 patent/WO2015070203A1/fr active Application Filing
- 2014-11-11 KR KR1020167015585A patent/KR102476969B1/ko active IP Right Grant
- 2014-11-11 RU RU2016122062A patent/RU2696584C1/ru active
- 2014-11-11 CA CA2928631A patent/CA2928631A1/fr active Pending
- 2014-11-11 CN CN202211672521.2A patent/CN116077548A/zh active Pending
- 2014-11-11 SG SG11201603462SA patent/SG11201603462SA/en unknown
-
2016
- 2016-04-27 PH PH12016500780A patent/PH12016500780A1/en unknown
- 2016-05-03 ZA ZA2016/02941A patent/ZA201602941B/en unknown
- 2016-05-09 IL IL245552A patent/IL245552B/en active IP Right Grant
- 2016-05-09 CL CL2016001109A patent/CL2016001109A1/es unknown
- 2016-05-10 US US15/150,722 patent/US20160324911A1/en not_active Abandoned
-
2018
- 2018-05-14 US US15/979,265 patent/US11045511B2/en active Active
-
2019
- 2019-08-05 US US16/532,367 patent/US10898534B2/en active Active
- 2019-10-23 US US16/661,749 patent/US11291703B2/en active Active
- 2019-11-22 JP JP2019211391A patent/JP7083330B2/ja active Active
-
2022
- 2022-02-28 US US17/682,190 patent/US20220175863A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL245552A0 (en) | Compositions and methods useful for treating symptoms of the lower urinary tract, benign prostatic hyperplasia and impotence | |
HK1220995A1 (zh) | 基於微生物的廢水處理組合物及其使用方法 | |
IL244665B (en) | Conjugates of chlorotoxin and methods of using them | |
IL273090B (en) | Methods and preparations for the treatment of cancer | |
EP3618914A4 (fr) | Dispositifs implantables et procédés de traitement d'une hyperplasie bénigne de la prostate (hbp) et des symptômes des voies urinaires inférieures (luts) associés | |
EP2675469A4 (fr) | Compositions, dispositifs et procédés d'utilisation de celles-ci dans le traitement des cancers | |
EP2950807A4 (fr) | Compositions et procédés à utiliser pour le traitement de troubles métaboliques | |
EP2831001A4 (fr) | Compositions de traitement des eaux et procédés d'utilisation | |
AP2011005943A0 (en) | Atropisomers of 2-purinyl-3-tolylquinazolinone derivatives and methods of use. | |
EP3061459A4 (fr) | Composition de traitement et de prévention de l'hypertrophie bénigne de la prostate | |
GB201320723D0 (en) | Composition and methods of treatment | |
PT2658551T (pt) | Tratamento da disfunção erétil e outras indicações | |
HUE054137T2 (hu) | NX-1207 jóindulatú prosztatamegnagyobbodásban szenvedõ páciensek kezelésében sebészeti beavatkozás szükségességének csökkentésére történõ alkalmazásra | |
HK1209792A1 (en) | Use of markers in the diagnosis and treatment of prostate cancer | |
ZA201109513B (en) | Composition for the treatment of benign prostate hyperplasia | |
WO2012073047A3 (fr) | Compositions et procédés | |
EP2908136A4 (fr) | Méthode et kit pour la distinction entre un cancer prostatique et une hypertrophie bénigne de la prostate | |
SG10201709955PA (en) | Methods of treatment and compositions with xanthine oxidase inhibitors | |
GB2479693B (en) | Steroidal CYP17 inhibitors and their use in the treatment of cancer and prostate hyperplasia | |
EP2968374A4 (fr) | Méthodes et compositions permettant d'améliorer le taux d'oxygène dans des tissus | |
EP2800568A4 (fr) | Compositions, procédés d'utilisation et procédés de traitement | |
EP2585109A4 (fr) | Compositions et méthodes de prévention et de traitement de lésion et/ou de dysfonctionnement d'organe | |
DK2916856T4 (da) | Anvendelser af bremelanotid til behandling af seksuel dysfunktion hos kvinder | |
GB201621183D0 (en) | Clopidogrel for use in the treatment of benign prostatic hyperplasia | |
PT2389936E (pt) | Aminaftona para utilização no tratamento e/ou prevenção de enxaqueca |